• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aprea Therapeutics Inc.

    2/14/24 8:00:11 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APRE alert in real time by email
    SC 13G 1 g19242sc13g.htm

     

    CUSIP No. 03836J201 Page 1 of 6
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
     
    Aprea Therapeutics, Inc.
    (Name of Issuer)
     
    Common stock, par value $0.001 per share
    (Title of Class of Securities)
     
    03836J201
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)
    ¨Rule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      
     

    CUSIP No. 03836J201 Page 2 of 6

     

    1.

    Names of Reporting Person

     

    I.R.S. Identification Nos. of Above Persons (entities only)

     

    Sio Capital Management, LLC

     

    20-4586565

    2.

    Check the Appropriate Box if a Member of a Group

     

     

    (a) ¨

    (b) ¨

    3.

    SEC Use Only

     

     
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially

    Owned by Each Reporting

    Person With1

    5.

    Sole Voting Power

     

    -0-
    6.

    Shared Voting Power

     

    280,0001
    7.

    Sole Dispositive Power

     

    -0-
    8.

    Shared Dispositive Power

     

    280,0001
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    280,000
    10.

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     

    ¨

    11.

    Percent of Class Represented by Amount in Row (9)

     

    7.49%2
    12. Type of Reporting Person IA
               

    _____________________

    1 As of December 31, 2023, Sio Capital Management, LLC beneficially owned 280,000 shares of Common Stock with shared voting power and shared dispositive power.

    2 Based on 3,736,673 shares of common stock outstanding as of November 9, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on November 13, 2023.

     

      
     

    CUSIP No. 03836J201 Page 3 of 6

     

    Schedule 13G

     

    Item 1(a).Name of Issuer:

     

      Aprea Therapeutics, Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

     

    535 Boylston Street

    Boston, MA 02116

     

    Item 2(a).Name of Persons Filing:

     

      This Statement is filed on behalf of Sio Capital Management, LLC (the “Reporting Person” or “Sio”)
       
      Sio is a registered investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.

     

    Item 2(b).Address of Principal Business Office:

     

     

    600 Third Avenue, 2nd Floor

    New York, New York 10016

     

    Item 2(c).Citizenship:

     

      Sio is a Delaware limited liability company.   

     

    Item 2(d).Title of Class of Securities:

     

      Common stock, par value $0.001

     

    Item 2(e).CUSIP Number:

     

      03836J201

     

      
     

    CUSIP No. 03836J201 Page 4 of 6

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.78c).
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) x An investment adviser in accordance with §13d-1(b)(1)(ii)(E).
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    ¨ If this statement is filed pursuant to §240.13d-1(c), check this box.

     

    Item 4.Ownership.

     

    (a) through (c):

     

    The information set forth in Items 5 through 9 and 11 of the cover pages to this Schedule 13G is incorporated herein by reference.3

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

      Not applicable.

     

      
     

    CUSIP No. 03836J201 Page 5 of 6

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.

     

      Not Applicable.

      

    Item 8.Identification and Classification of Members of the Group.

     

      Not Applicable.

     

    Item 9.Notice of Dissolution of a Group.

     

      Not Applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to herein were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

      
     

    CUSIP No. 03836J201 Page 6 of 6

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 6, 2024

     

      SIO CAPITAL MANAGEMENT, LLC  
         
        By: /s/ Jin W. Lee  
             
        Name:  Jin W. Lee  
        Title: Chief Compliance Officer  

     

     

     

     

     

    Get the next $APRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APRE

    DatePrice TargetRatingAnalyst
    8/20/2021Neutral → Underweight
    JP Morgan
    8/16/2021Buy → Hold
    Berenberg
    8/16/2021$6.00 → $4.00Neutral
    HC Wainwright & Co.
    8/13/2021$6.00 → $5.00Sector Perform
    RBC Capital
    8/13/2021$5.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $APRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Seizinger Bernd R. was granted 1,045 shares, increasing direct ownership by 2% to 45,775 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      6/9/25 4:07:40 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Peters Richard was granted 1,045 shares, increasing direct ownership by 50% to 3,119 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      6/9/25 4:06:53 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pamukcu Rifat was granted 1,045 shares, increasing direct ownership by 24% to 5,446 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      6/9/25 4:06:08 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRE
    SEC Filings

    See more
    • Aprea Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)

      6/9/25 4:01:31 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.

      SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      5/14/25 4:04:41 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aprea Therapeutics Inc.

      10-Q - Aprea Therapeutics, Inc. (0001781983) (Filer)

      5/14/25 8:10:23 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care